This preprint is under consideration at Journal of Ovarian Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Pretreatment Thrombocytosis as an Independent Predictive Factor for Chemoresistance and Poor Survival in Epithelial Ovarian Cancer
Takeo Minaguchi
Tsukuba Daigaku Igaku Iryokei
Corresponding Author
ORCiD: https://orcid.org/0000-0003-3577-5124
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Methods We retrospectively analyzed 280 consecutive patients who were treated for epithelial ovarian cancer at our institution between 2001 and 2011.
Results Pretreatment thrombocytosis was observed in 18.9% of all patients and was associated with advanced FIGO stage, primary treatment, operation achievement, histologic subtype, microcytic hypochromic anemia (MHA), and nonmalignant inflammatory condition ( P =0.0018, 0.0028, 0.00050, 0.034, 0.00090 and 0.0022). In the patients who relapsed after primary adjuvant chemotherapy (n=126), thrombocytosis was associated with a shorter treatment-free interval (TFI) ( P =0.0091). The univariate and multivariate analyses revealed that thrombocytosis was independently associated with TFI and MHA ( P =0.021 and 0.0091). Patients with thrombocytosis had worse progression-free survival (PFS) and overall survival (OS) than those without thrombocytosis ( P <0.0001 and <0.0001). The multivariate analyses for prognostic factors demonstrated that thrombocytosis was significant for poor PFS and OS ( P =0.0050 and 0.022) independent of stage, histology, primary treatment, operation achievement, nonmalignant inflammatory condition and MHA.
Conclusions The current findings indicate that the detrimental survival impact of pretreatment thrombocytosis in epithelial ovarian cancer may be independent of tumor extent but rather attributed to chemoresistance, further supporting the therapeutic potential of targeting thrombopoietic cytokines in the disease.
Keywords
thrombocytosis, ovarian cancer, survival
Figure 1
Figure 2
Due to technical limitations the Tables are available as a download in the Supplemental Files.
Table 1. Patient characteristics.
Table 2. Relationships between pretreatment thrombocytosis and clinicopathologic parameters.
Table 3. Univariate and multivariate analyses of risk factors for pretreatment thrombocytosis.
Table 4. Univariate and multivariate analyses of prognostic factors for PFS and OS.
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 17 Apr, 2020
No community comments so far
Editor assigned
On 14 Apr, 2020
Submission checks complete
On 13 Apr, 2020
Editor invited
On 13 Apr, 2020
No comments provided
Review #1 received
Received 18 Mar, 2020
Editorial decision: Minor revision
On 18 Mar, 2020
Reviewer #4 agreed
On 11 Mar, 2020
Reviewer #3 agreed
On 10 Mar, 2020
Reviewer #2 agreed
On 07 Mar, 2020
Review #2 received
Received 07 Mar, 2020
Reviewer #1 agreed
On 06 Mar, 2020
Reviewers invited
Invitations sent on 04 Mar, 2020
Editor assigned
On 21 Feb, 2020
First submitted
On 20 Feb, 2020
Submission checks complete
On 20 Feb, 2020
Editor invited
On 20 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Journal of Ovarian Research. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Pretreatment Thrombocytosis as an Independent Predictive Factor for Chemoresistance and Poor Survival in Epithelial Ovarian Cancer
Takeo Minaguchi
Tsukuba Daigaku Igaku Iryokei
Corresponding Author
ORCiD: https://orcid.org/0000-0003-3577-5124
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 17 Apr, 2020
No community comments so far
Editor assigned
On 14 Apr, 2020
Submission checks complete
On 13 Apr, 2020
Editor invited
On 13 Apr, 2020
No comments provided
Review #1 received
Received 18 Mar, 2020
Editorial decision: Minor revision
On 18 Mar, 2020
Reviewer #4 agreed
On 11 Mar, 2020
Reviewer #3 agreed
On 10 Mar, 2020
Reviewer #2 agreed
On 07 Mar, 2020
Review #2 received
Received 07 Mar, 2020
Reviewer #1 agreed
On 06 Mar, 2020
Reviewers invited
Invitations sent on 04 Mar, 2020
Editor assigned
On 21 Feb, 2020
First submitted
On 20 Feb, 2020
Submission checks complete
On 20 Feb, 2020
Editor invited
On 20 Feb, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
Methods We retrospectively analyzed 280 consecutive patients who were treated for epithelial ovarian cancer at our institution between 2001 and 2011.
Results Pretreatment thrombocytosis was observed in 18.9% of all patients and was associated with advanced FIGO stage, primary treatment, operation achievement, histologic subtype, microcytic hypochromic anemia (MHA), and nonmalignant inflammatory condition ( P =0.0018, 0.0028, 0.00050, 0.034, 0.00090 and 0.0022). In the patients who relapsed after primary adjuvant chemotherapy (n=126), thrombocytosis was associated with a shorter treatment-free interval (TFI) ( P =0.0091). The univariate and multivariate analyses revealed that thrombocytosis was independently associated with TFI and MHA ( P =0.021 and 0.0091). Patients with thrombocytosis had worse progression-free survival (PFS) and overall survival (OS) than those without thrombocytosis ( P <0.0001 and <0.0001). The multivariate analyses for prognostic factors demonstrated that thrombocytosis was significant for poor PFS and OS ( P =0.0050 and 0.022) independent of stage, histology, primary treatment, operation achievement, nonmalignant inflammatory condition and MHA.
Conclusions The current findings indicate that the detrimental survival impact of pretreatment thrombocytosis in epithelial ovarian cancer may be independent of tumor extent but rather attributed to chemoresistance, further supporting the therapeutic potential of targeting thrombopoietic cytokines in the disease.
Figure 1
Figure 2
Due to technical limitations the Tables are available as a download in the Supplemental Files.
Table 1. Patient characteristics.
Table 2. Relationships between pretreatment thrombocytosis and clinicopathologic parameters.
Table 3. Univariate and multivariate analyses of risk factors for pretreatment thrombocytosis.
Table 4. Univariate and multivariate analyses of prognostic factors for PFS and OS.